Quince's High-Stakes Pivot: A New Future with Inhaled Drug LAM-001

SOUTH SAN FRANCISCO, CA – August 14, 2026 – In a decisive move that redefines its corporate identity, Quince Therapeutics has executed a dramatic strategic pivot, transforming from a company with a winding-down research program into a focused, late-stage player in the high-need area of rare pulmonary diseases. The company announced the completion of its acquisition of Orphai Therapeutics, bringing the promising clinical-stage asset LAM-001 into its fold. Underpinning this transformation is a concurrent $115 million private placement, arming Quince with the capital to pursue a new, singular mission: to develop what could be a disease-modifying therapy for several devastating lung conditions.

A Strategic Overhaul Born from Necessity

This week’s announcements represent more than just a new chapter for Quince; they signify a complete strategic rebirth. The company’s recent history was marked by challenges, including the acknowledged “wind down of the eDSP program,” a clear signal that its prior research focus had reached a dead end. Furthermore, the company executed two reverse stock splits in quick succession—a 1-for-10 split in April followed by a 1-for-20 split in June 2026. Such moves are often undertaken by companies to shore up a flagging share price and maintain NASDAQ listing requirements, pointing to a period of significant pressure.

Financial analyses from earlier in the year suggested a company with a stable but underutilized balance sheet and significant profitability challenges. The acquisition of Orphai and its lead asset, therefore, is not merely an opportunistic expansion but a calculated, high-stakes maneuver to inject new life and a clear clinical path into the organization. By acquiring a late-stage asset with compelling early data, Quince has effectively swapped its uncertain past for a well-defined, albeit challenging, future in pulmonary medicine.

The Science Behind a New Hope for Lungs

At the heart of Quince’s new strategy is LAM-001, an investigational inhaled formulation of rapamycin (also known as sirolimus). The drug targets the mTOR pathway, a central signaling network that, when overactive, drives the inflammation, uncontrolled cell proliferation, and fibrosis characteristic of severe lung diseases. While oral rapamycin is a potent mTOR inhibitor, its systemic use can lead to significant side effects. LAM-001’s innovation lies in its delivery system: a once-daily inhaled formulation designed to concentrate the drug directly in the lungs, maximizing therapeutic impact while minimizing systemic exposure.

This approach is not merely theoretical. Quince is building on compelling Phase 2a data presented at the American Thoracic Society (ATS) Conference in May. In that open-label study involving patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), treatment with LAM-001 led to clinically meaningful improvements. Patients demonstrated a mean improvement of 67.4 meters in the six-minute walk distance (6MWD)—a critical measure of exercise capacity and quality of life. They also showed a mean reduction in pulmonary vascular resistance (PVR) of 33.9%, indicating a direct, positive effect on the underlying cardiopulmonary mechanics of the disease. The drug was generally well-tolerated, a key consideration for a therapy aimed at a fragile patient population.

“We are pleased to have initiated the Phase 2b trial of LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) and look forward to releasing top line bronchiolitis obliterans syndrome post lung transplant (BOS) data in the first quarter of next year,” stated Dr. Brigette Roberts, former CEO of Orphai Therapeutics and now Chief Corporate Affairs Officer of Quince. She emphasized that mTOR inhibition via LAM-001 “has the potential to offer PH-ILD and BOS patients a new treatment option that is designed to target and potentially reverse key elements of the underlying pathophysiology of these devastating diseases.”

Fortifying the Balance Sheet for the Clinical Road Ahead

Developing a late-stage asset requires immense capital, and Quince’s financial maneuvers appear tailored to meet this demand. The company secured $115 million in gross upfront proceeds from a private placement, netting $103.6 million after expenses. This infusion boosts its cash and cash equivalents to $116 million as of June 30, 2026. Critically, this provides a projected cash runway through the end of 2028, a timeframe that covers several key anticipated clinical data readouts for LAM-001.

The company reported a net loss of $75.5 million for the second quarter, a figure that could alarm investors at first glance. However, a closer look reveals that the loss is heavily skewed by one-time, non-cash charges directly related to the acquisition. These include a $59 million charge for acquired in-process research and development (IPR&D) and a significant increase in general and administrative expenses due to stock-based compensation and restructuring fees. This distinction is vital, as it separates strategic investment costs from underlying operational burn.

Furthermore, the financing structure includes warrants that, if exercised, could provide up to an additional $83 million. This provides a secondary source of potential funding that could extend the company's operational runway even further, offering a buffer against the inherent uncertainties of clinical development.

Targeting a Void in Pulmonary Medicine

Quince is now positioned to tackle three severe pulmonary diseases with significant unmet needs. For PH-ILD, which affects an estimated 200,000 patients across the U.S. and Europe, LAM-001 offers the potential of a disease-modifying agent in a field where many treatments only manage symptoms. The market opportunities in the other target indications are even more distinct.

Bronchiolitis obliterans syndrome (BOS), a common and deadly complication following lung transplant, currently has no approved therapies. Likewise, sarcoidosis-associated pulmonary hypertension (SAPH), a severe complication of sarcoidosis, also lacks an approved treatment. For the tens of thousands of patients suffering from BOS and SAPH, a successful LAM-001 could represent not just a new option, but the first-ever approved therapy. With a fully enrolled Phase 2 trial in BOS expected to yield data in early 2027 and a new Phase 2 trial in SAPH slated to begin later this year, Quince has a clear and aggressive timeline to prove its new asset’s worth.